Physician profile
Albert J Belli
NPI 1184631012
$4,844.61
in general payments reported to CMS, 2019-2025
27 companies · $750 in 2025
The $750 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,053 · 2020: $655 · 2021: $610 · 2022: $802 · 2023: $398 · 2024: $577 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.68 |
| Education | $226.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,055.56 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $718.02 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Actelion Pharmaceuticals US, INC. | $427.78 | 2019-2025 | Uptravi, Opsumit |
| Philips North America LLC | $406.33 | 2019-2025 | (Ak6) Vest Therapy, Incourage Airway Clearance Therapy, Vest Therapy Und |
| Insmed, INC. | $283.70 | 2019-2025 | Arikayce |
| Genzyme Corporation | $279.82 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $265.93 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $210.77 | 2019-2024 | Yupelri |
| United Therapeutics Corporation | $205.45 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.06 | 2020-2024 | Ofev |
| Genentech USA, INC. | $138.62 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $84.99 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.88 | 2019-2021 | |
| Harmony Biosciences LLC | $70.88 | 2022 | |
| Verona Pharma, INC. | $64.98 | 2025 | Ohtuvayre |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $58.51 | 2019-2021 | |
| Grifols USA, LLC | $55.24 | 2019-2024 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $40.03 | 2019-2024 | Winrevair |
| Sunovion Pharmaceuticals INC. | $39.40 | 2019 | |
| Baxter Healthcare | $37.57 | 2025 | |
| Viatris Specialty LLC | $32.39 | 2025 | Yupelri |
| Electromed, INC. | $28.73 | 2022 | |
| Mallinckrodt Enterprises LLC | $25.85 | 2019 | |
| Medtronic, INC. | $22.87 | 2021 | |
| Ethicon INC. | $19.93 | 2021 | |
| Inspire Medical Systems, INC. | $17.51 | 2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $13.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Belli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.